Literature DB >> 1003104

The binding of human lactoferrin to mouse peritoneal cells.

J L Van Snick, P L Masson.   

Abstract

Human iron-saturated Lf (FeLf), which was labeled with 125I or 50Fe, was found to combine with the membrane of mouse peritoneal cells (MPC) which consisted of 70% macrophages. The following experimental data suggested the involvement of a specific receptor. (a) The binding of FeLf to MPC reached a saturation point. (b) The binding of radioactive FeLf was inhibited by preincubating the cells with cold FeLf but not with human Tf, human aggregated and nonaggregated IgG, or beef heart cytochrome c (c) Succinylation and carbamylation of FeLf resulted in a loss of its inhibiting activity on the binding of radioactive FeLf. Removal of neuraminic acid from FeLf increased its inhibitory activity. (d) The ability of apoLf to inhibit the binding of FeLf to MPC was significantly lower than that of FeLf. The existence of a Lf receptor capable of concentrating Lf released from neutrophils on the membrane of macrophages could explain the apparent blockade of the release of iron from the reticuloendothelial system, which accounts for the hyposideremia of inflammation. A receptor for FeLf was also found on mouse peritoneal lymphocytes. The affinity constant of FeLf for both lymphocytes and macrophages was 0.9 X 12(6) liter/mol. Howerver, macrophages bound three times more FeLf molecules (20 X 10(6)) per cell than did lymphocytes (7 X 10(6)).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003104      PMCID: PMC2190488          DOI: 10.1084/jem.144.6.1568

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  IRON UPTAKE BY ERYTHROPOIETIC AND OTHER TISSUES FROM "NATIVE" SERUM SIDEROPHILIN AND FROM ISOLATED "PURIFIED" SIDEROPHILIN.

Authors:  A L SCHADE
Journal:  Farmaco Sci       Date:  1964-02

2.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

3.  [Preparation and properties of lactosiderophilin (lactotransferrin) of human milk].

Authors:  J MONTREUIL; J TONNELAT; S MULLET
Journal:  Biochim Biophys Acta       Date:  1960-12-18

4.  Amino acid sequence of cysteic peptides of lactoferrin and demonstration of similarities between lactoferrin and transferrin.

Authors:  J M Bluard-Deconinck; P L Masson; P A Osinski; J F Heremans
Journal:  Biochim Biophys Acta       Date:  1974-10-09

5.  Inhibition of bacteria by lactoferrin and other iron-chelating agents.

Authors:  J D Oram; B Reiter
Journal:  Biochim Biophys Acta       Date:  1968-12-23

6.  Serum lactoferrin in leukaemia and polycythaemia vera.

Authors:  J Malmquist
Journal:  Scand J Haematol       Date:  1972

7.  Iron transport intermediates in human reticulocytes and the membrane binding site of iron-transferrin.

Authors:  J Fielding; B E Speyer
Journal:  Biochim Biophys Acta       Date:  1974-09-23

8.  Iron-binding proteins in milk and resistance to Escherichia coli infection in infants.

Authors:  J J Bullen; H J Rogers; L Leigh
Journal:  Br Med J       Date:  1972-01-08

9.  The involvement of lactoferrin in the hyposideremia of acute inflammation.

Authors:  J L Van Snick; P L Masson; J F Heremans
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

10.  THE DIFFERENTIATION OF MONONUCLEAR PHAGOCYTES. MORPHOLOGY, CYTOCHEMISTRY, AND BIOCHEMISTRY.

Authors:  Z A COHN; B BENSON
Journal:  J Exp Med       Date:  1965-01-01       Impact factor: 14.307

View more
  32 in total

1.  Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin.

Authors:  Irini Bournazou; John D Pound; Rodger Duffin; Stylianos Bournazos; Lynsey A Melville; Simon B Brown; Adriano G Rossi; Christopher D Gregory
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

2.  Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for iron-binding proteins in the control of lymphoid cell migration.

Authors:  M de Sousa; A Smithyman; C Tan
Journal:  Am J Pathol       Date:  1978-02       Impact factor: 4.307

3.  Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.

Authors:  F Kievits; A Kijlstra
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

4.  Primary structure of glycans isolated from human leucocyte lactotransferrin. Absence of fucose residues questions the proposed mechanism of hyposideraemia.

Authors:  P Derisbourg; J M Wieruszeski; J Montreuil; G Spik
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

5.  Interleukin 1 administration in mice produces hypoferremia despite neutropenia.

Authors:  V R Gordeuk; P Prithviraj; T Dolinar; G M Brittenham
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

6.  Increased in vivo secretory activity of neutrophil granulocytes in patients with psoriasis and palmoplantar pustulosis.

Authors:  A Lundin; L Håkansson; R Hällgren; G Michaëlsson; P Venge
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

Review 7.  Lactoferrin as a natural immune modulator.

Authors:  Jeffrey K Actor; Shen-An Hwang; Marian L Kruzel
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Iron-binding fragments from the N-terminal and C-terminal regions of human lactoferrin.

Authors:  J M Bluard-Deconinck; J Williams; R W Evans; J van Snick; P A Osinski; P L Masson
Journal:  Biochem J       Date:  1978-05-01       Impact factor: 3.857

9.  Immunological studies of human placentae: identification and distribution of proteins in immature chorionic villi.

Authors:  P M Johnson; W P Faulk
Journal:  Immunology       Date:  1978-06       Impact factor: 7.397

10.  Membrane-bound lactoferrin alters the surface properties of polymorphonuclear leukocytes.

Authors:  L A Boxer; R A Haak; H H Yang; J B Wolach; J A Whitcomb; C J Butterick; R L Baehner
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.